For General Information, page-467

I thought that $74 mill to fund the pivotal trial and cover G&A for the duration seemed a steep number for 108-114 trial patients. In looking at the application of funds back in the CR presentation, I noticed that drug manufacture was estimated to cost $7.4 mill to futility, which is effectively the half way point (I assume Ionis are the manufacturer). Let’s assume that drug manufacture for the entire trial costs twice this, which is $14.8 mill. Only two thirds of the trial patients (72-76) are receiving ATL1102 (one third receive placebo/SOC only). That means, the annual cost per patient in the trial comes to approximately $200,000 or $4,000 per weekly jab. As this is the revenue per year estimated per patient once commercialised (used when they calculated their $4 bill TAM), I hope we can manufacture at a much reduced cost, assuming commercialisation success, to extract SOME margin. Secondly, why do Ionis get to charge this figure pre-commercialisation and 3 years after their ATL1102 patents have expired?